Live feed
Filing
SCHEDULE 13G
SCHEDULE 13G0001193125-25-284205·Cytek Biosciences, Inc.
Schedule 13G ownership disclosure
Cytek Biosciences Inc
Common Stock - $0.001 par value · CUSIP: 23285D109
Event date: 2025-09-25
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Topline Capital Management, LLC
Shares: 6,780,847 · Class: 5.3%
- Collin McBirney
Shares: 6,780,847 · Class: 5.3%
- Topline Capital Partners, LP
Shares: 6,780,847 · Class: 5.3%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001193125-25-284205
- Form type
- SCHEDULE 13G
- Filer
- Cytek Biosciences, Inc.
- CIK
- CIK 1831915
- Filed
- Nov 17, 2025
- Reporting period
- Sep 25, 2025
- Description
- Schedule 13G beneficial ownership